Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

Novo Nordisk NVO shares have lost 15.2% so far ... In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in ...

as well as the launches of Mim8 and amycretin. What do I expect from Eli Lilly in the long term? I estimate Eli Lilly's non-GAAP EPS and revenue growth will be higher than Novo Nordisk's over the ...